Bearish Divergence on the 1 hr chart. I am selling short here. Quick trade, as it is the 1 hr after all.
NASDAQ:KPTI Possible Scenario: Long Evidence: Price Action, IH&S, Money-Flow TP1: 7.85$ Call options, 01/21/2022, Strike 7.5$ *This is my idea and could be wrong 100%
Possible flag above 8.53, Stop signal 7.81, Target 1 9.87 , Target 2 Momentum
Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma SHANGHAI and HONG KONG, April 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global...
This one was brought to my attention by California Hip Hop Rap Underrated during ChampionVibe's Livestream a few days ago. I see this withing a channel while maybe looking left it could also look like a ascending broadening wedge which should be taken into account. Risk management is easy here and there is an edge for the bulls on the osciliators so I will play...
The chart is consolidating in range of 14 after having made a huge cup and coning out of handle pattern, may start uprun towards 20, SL:13.75. Once the cup and handle pattern give successful breakout near 20, may cross 30. Disclaimer: The stock/index/currency discussed do not constitute Investment/trading advise and is merely an effort towards enhancing learning,...
KPTI has been trading in a range with Earnings expected on Feb. 11. Experts expect KPTI to grow exponentially over next few years. At worst, swing this from 15 - 17.5. At best, buy at 15 and hold until breakout.
KPTI: Karyopharm Therapeutics Inc. 2020-12-18 11:30:00 Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
Forming a penant. Broke out of its diagonal R/S line, now going up against the main trend diagonal. RSI looking healthy, trend is its favor.
KPTI: Karyopharm Therapeutics Inc. 2020-06-22 11:25:10 Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
looking good for a throwback on a cup & handle.
Should manage to move between those trend lines.
watch for price/volume actions at these prices on support and resistance lines and jump in or out based on that.